ClinicalTrials.gg
CompletedNCT06775405Updated Oct 28, 2026

A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

A Phase 3 interventional study of AK0529 and Placebo in Respiratory Synctial Virus Infections, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 17 sites in China. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2024, registered Dec 2024).
Updated Oct 28, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
1 Month to 24 Months
Sex
All
01

Study summary

Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in infants. Serious respiratory problems such as pneumonia caused by RSV are one of the leading causes of death from respiratory diseases in infants. AK0529 targets the Pre-F (fusion) protein on the surface of the viral envelope. Specifically, it prevents the virus from invading uninfected cells and inhibits the fusion between host cells by inhibiting the fusion of the F (fusion) proteins on the surface of the RSV envelope, thus providing the effects of anti-RSV infection. This is a randomized, double-blind, placebo-controlled, multicenter, phase III clinical study to evaluate the efficacy and safety of AK0529 in hospitalized infants aged 1 to 24 months with RSV infection. Considering the benefits of AK0529 in the population with RSV infection, hospitalized infants with moderate to severe RSV infection were selected as the target population for this study.

Read the detailed description

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter clinical study conducted among Chinese infants aged 1 to 24 months hospitalized with Respiratory Syncytial Virus (RSV) infection.

The study plans to enroll 180 infants aged 1 to 24 months with RSV infection. Eligible subjects will be randomized in a 1:1 ratio (AK0529: placebo). These subjects will receive the study drug twice daily for 5 consecutive days and the dose depends on subject's weight range.

Each subject in this study will undergo a visit schedule comprising a screening period of 36 hours before the first dose, a 5-day double-blinded treatment period, and a 9-day safety follow-up period after the last dose of treatment. The expected duration of participation for each subject will not exceed 17 days.

Infants successfully enrolled in this study will take the medication every 12 hours for 5 consecutive days, in total 10 doses. Investigators will regularly score the infants using the Wang bronchiolitis clinical score which is the primary endpoint. Additionally, nasopharyngeal aspirates samples will be collected from the infants for virological testing before the first dose on Days 1 to 5, on Day 6, and on Day 14.

Safety and tolerability assessments in this study will include evaluations of adverse events (AEs)/serious adverse events (SAEs), vital signs and blood oxygen saturation (SpO2) levels, physical examinations, clinical laboratory tests, and electrocardiogram (ECG) findings.

02

Conditions studied

  • Respiratory Synctial Virus Infections
03

In context

Lead sponsor

Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion criteria:

  1. Male or female subjects of any ethnicity with an age adjusted for any prematurity of ≥1 month and ≤24 months.
  2. Diagnosis of RSV infection by any virological means, including a rapid diagnostic point-of-care testing, within 36 hours preceding initial dosing.
  3. The onset of RSV infection symptoms should be ≤ 5 days prior to initial dosing.
  4. Subject must weigh ≥ 2.5 kg and ≤ 20 kg at screening and be within the normal range for the subject's age, based on local child growth standards.
  5. Subject must have a Wang bronchiolitis clinical score ≥ 5.

Main Exclusion criteria:

  1. The subject has taken any restricted medications within 3 days prior to the date of screening or requires any restricted medications during treatment phase (including interferons, ribavirin, or proprietary Chinese medicines with antiviral effects) and has taken any inhaled or systemic within 24 hours.
  2. Subject is known to have co-infection with influenza virus, Mycoplasma, or other respiratory tract pathogens that require targeted clinical treatment .
  3. Subject is known to have bacterial pneumonia.
  4. Subject with clinical evidence of hepatic decompensation (e.g., liver disease with coagulation abnormalities or encephalopathy).
  5. Subject with inborn symptoms of metabolic abnormalities (e.g., mitochondrial diseases, carbohydrate metabolism abnormalities, glycogen accumulation diseases).
  6. Subject with chronic or persistent feeding difficulties.
  7. The parent or guardian of the subject is an employee of the study investigator or the study facility (such person will be directly involved in the study or any other study administered by the study facility investigator), or a family member of the study investigator or his/her staff.
  8. Subject who have participated in clinical trials of other drugs or devices in the 30 days prior to screening.
  9. Subject with any other reason that the investigator deems unsuitable for participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Active drug

    The participants will receive AK0529 of 10 mg, 20 mg or 40 mg based on body weight twice daily for 5 days from D1 to D5.

    Drug: AK0529

  • Placebo comparator
    Placebo

    The participants will receive placebo of 10 mg, 20 mg or 40 mg based on body weight twice daily for 5 days from D1 to D5.

    Drug: Placebo

Interventions

  • DrugAK0529

    Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral

  • DrugPlacebo

    Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Wang bronchiolitis clinical score

    The Wang bronchiolitis clinical score will be used to evaluate respiratory rate, wheezing, respiratory muscle retraction and "general condition" (sleep, feeding, and general status) in subjects with symptoms of bronchiolitis. Each item of the scale is divided into 4 levels according to the severity of symptoms, with 0 point indicating normal and 3 points the highest severity, 12 points in total.

    Time frame: Day 3 (48 hours)

Secondary outcomes

  1. Change from baseline in the Wang bronchiolitis clinical score in subjects younger than 6 months.

    The Wang bronchiolitis clinical score will be used to evaluate respiratory rate, wheezing, respiratory muscle retraction and "general condition" (sleep, feeding, and general status) in subjects with symptoms of bronchiolitis. Each item of the scale is divided into 4 levels according to the severity of symptoms, with 0 point indicating normal and 3 points the highest severity, 12 points in total.

    Time frame: Day 3 (48 hours)

  2. Time from first treatment to sustained remission of symptoms during the treatment period.

    The sustained remission is defined as achieving a total Wang bronchiolitis clinical score of 0 or 1 for 48 consecutive hours without support of oxygen therapy.

    Time frame: Study period (up to 14 days)

  3. Change in RSV VL (viral load) from baseline at each visit.

    The viral load of subjects' nasopharyngeal samples will be measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

    Time frame: Day 2, Day 3, Day 4, Day 5, Day 6, Day 14

  4. Proportion of subjects with RSV VL below the lower limit of quantitation (LLOQ) at each visit.

    The viral load of subjects' nasopharyngeal samples will be measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

    Time frame: Day 2, Day 3, Day 4, Day 5, Day 6, Day 14

  5. Time from first treatment to mild disease for subjects, defined as achieving a Wang bronchiolitis clinical score ≤ 3 without the need for supplemental oxygen.

    Time frame: Study period (up to 14 days)

  6. Change in sub-scores of the Wang bronchiolitis clinical score from baseline at each visit.

    The Wang bronchiolitis clinical score will be used to evaluate respiratory rate, wheezing, respiratory muscle retraction and "general condition" (sleep, feeding, and general status) in subjects with symptoms of bronchiolitis. Each item of the scale is divided into 4 levels according to the severity of symptoms, with 0 point indicating normal and 3 points the highest severity, 12 points in total.

    Time frame: Day 2, Day 3, Day 4, Day 5, Day 6, Day 14

  7. Time from initial dosing to resolution of symptoms based on sub-scores of the Wang bronchiolitis clinical score.

    The resolution is defined as achieving the following sub-scores without the need for supplemental oxygen: * Respiratory rate = 0 or 1 * Wheezing = 0 or 1 * Respiratory muscle retraction = 0 or 1 * General condition = 0 Note: The above indicators are only for subjects with a baseline sub-score greater than 0 for the respective sub-scores.

    Time frame: Study period (up to 14 days)

  8. Safety endpoints

    The safety assessment includes the following events, tests, indicators occurring during the study process: * Incidence rate and severity of Adverse Events (AEs), Serious Adverse Events (SAEs), and withdrawal from the study due to AEs; * Laboratory tests; * Electrocardiogram (ECG); * Physical examination and vital signs.

    Time frame: Study period (up to 14 days)

  9. Pharmacokinetic endpoints

    Include but not limit to steady state AUC, Cmax and Ctrough.

    Time frame: Study period (up to 14 days)

07

Study locations

17 sites
  • Beijing Children's Hospital, Capital Medical University
    Beijing, China
  • First Hospital of Jilin University
    Changchun, China
  • Hunan Provincial People's Hospital
    Changsha, China
  • West China Second University Hospital, Sichuan University
    Chengdu, China
  • Children's Hospital, Zhejiang University School of Medicine
    Hangzhou, China
  • Sanya Central Hospital, Hainan Third People's Hospital
    Sanya, China
  • Shanghai Children's Hospital, Shanghai Jiao Tong University
    Shanghai, China
  • Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • Shengjing Hospital of China Medical University
    Shenyang, China
  • Tianjin Children's Hospital(Longyan)
    Tianjin, China
  • Tianjin Children's Hospital(Machang)
    Tianjin, China
  • Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
    Wenzhou, China
  • Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
  • Wuxi Children's Hospital
    Wuxi, China
  • First Affiliated Hospital of Xiamen University
    Xiamen, China
  • Women and Children's Hospital, and the School of Medicine, Xiamen University
    Xiamen, China
  • Zhongshan Women and Children's Hospital-Zhongshan Boai Hospital
    Zhongshan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2024 to primary completion in Apr 2025, 13 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Aug 2025 → Apr 2025 and completion Sep 2025 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Jan 15, 2025
StartActual
Feb 29, 2024
Primary completionActual
Apr 7, 2025was Aug 2025
CompletionActual
Apr 16, 2025was Sep 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Sites
1 site removed
Show 1 removed
  • Beijing Children's Hospital, Capital Medical University · Beijing, China
Oct 28, 2026
Primary completion
Aug 2025→Apr 7, 2025 (actual)
Oct 28, 2026
Study completion
Sep 2025→Apr 16, 2025 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • Beijing Children's Hospital, Capital Medical University · Beijing, China
    Primary completion Aug 2025→Apr 7, 2025 (now actual)
    Study completion Sep 2025→Apr 16, 2025 (now actual)
    + 5 other changes: index terms, identifiers, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06775405
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Feb 29, 2024
Primary completion
Apr 7, 2025
Completion
Apr 16, 2025
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion